Clinical trials located in

Ksawerów

Ksawerów city is located in Poland. Currently, 7 clinical trials are being conducted in this city.

Ksawerów, a quaint city in Poland, nestled in the Łódź Voivodeship, boasts a rich history dating back to its first mention in 1386. Despite its small size, it plays a significant role in the region’s economy, primarily through its thriving textile industry, a legacy of the 19th-century industrial boom. The city’s landscape is marked by the picturesque Mroga River, adding to its serene charm. Ksawerów is also known for its commitment to sports, with facilities and clubs fostering local talent, particularly in volleyball. This city seamlessly blends its historical roots with a vibrant community spirit.

  • CT-EU-00056995

    Testing the effect of the new drug on Crohn’s Disease

    This study is exploring a new medication for Crohn’s disease, an ailment of the gut. The medication, known as BI 706321, is given alongside another medication called Ustekinumab that is already used to treat Crohn’s. The trial is conducted to see if this combination helps to manage the disease better. Participants will be split into two groups. One group will be given the new medication and the other will receive a placebo, alongside Ustekinumab. Participating in this study will last for 1 year. During this time, participants will have about 13 visits to the clinic. Some visits will involve a colonoscopy where doctors look at the intestine’s condition. Their findings will help doctors understand if the new treatment is working.

    • BI 706321- new potential medication for Crohn’s disease
    • ustekinumab
  • Continued study of ozanimod for severe Crohn’s Disease

    This research is about an extended study on the use of an oral medication named Ozanimod for people suffering from Crohn’s disease. Crohn’s disease can make the stomach and intestines really uncomfortable, causing swellings and pain. The main aim of this study is to check if this medicine, Ozanimod, is safe for intake and how effective it is in easing these uncomfortable feelings in the stomach. The researchers will rate patients’ illnesses using the Crohn’s Disease Activity Index (a measurement tool).

    • Ozanimod
  • Studying ozanimod as ongoing treatment for Severe Crohn’s Disease

    This trial is to test a medication called Ozanimod on people who have a serious type of Crohn’s Disease. Crohn’s Disease can make the stomach hurt a lot and sometimes makes difficulty eating.  The researchers want to see if the medication helps to calm the disease, so patients feel better. Some patients will get the Ozanimod and others will get a placebo.  The researchers use  ‘Crohn’s Disease Activity Index’ to see how the disease is doing.

    • Ozanimod
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Poland:

.